Biotech Values

[jq1234]

For example, ARQL enrolled non-squamous nsclc hoping it would capture a high percentage of MET+ pts however in the MetMab trial the hazard ratio for PFS in this same patient population was only .98 The same is true for the mutant KRAS cohort where MetMab basically showed no improvement over placebo (HR=1.04) while Tivantinib had an HR=0.18.

I would caution when compare ARQ197 ph2 vs MetMab ph2 literally because ARQL didn't have all patient samples tested via IHC, thus we don't know the true composition of Met high vs low. Bold above could be easily explained by the composition of Met high vs low in ARQL ph2 trial different from MetMab trial, mutant KRAS cohort result in ARQL ph2 might be skewed due to unusually high Met high patients in that small sample.